BLCO vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 2/9, indicating weak operational and balance sheet performance. Despite a reasonable Price/Book of 0.94 and a Debt/Equity ratio of 0.76, the company is unprofitable with a negative ROE of -4.50% and a profit margin of -6.13%. Earnings have collapsed year-over-year (-147.1%) and the last four quarters missed estimates by an average of -154.31%, signaling deteriorating fundamentals. While revenue growth of 7.10% and a gross margin above 59% provide some operational strength, the persistent earnings deterioration and lack of profitability undermine valuation support.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BLCO vs LLY: Head-to-Head Comparison
This page compares Bausch + Lomb Corporation (BLCO) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.